Autism, Diabetes, Cancer & Pain in New IMI Call for Proposals

IMIAutism, diabetes, cancer and pain are among the topics for the €348 million 10th Call for proposals launched under the IMI2 programme. Other topics in the Call focus on: the creation of a European network for clinical trials in children; the biomanufacture of certain medicines; the need to include the patient perspective in medicines development; and the role of certain genes in disease.

Half (€174 million) of the Call's budget comes from the EU’s Horizon 2020 programme and will fund the participation of organisations like universities, small-to-mid-sized companies, and patient groups in the projects. The other half comes from EFPIA companies and IMI Associated Partners, including JDRF, T1DExchange and the Helmsley Charitable Trust (for the diabetes topic) and Autism Speaks and the Simons Foundation Autism Research Initiative (SFARI) for the autism topic.

Pierre Meulien, IMI Executive Director commented: "The Associated Partners in this Call are all contributing their own funds and resources to IMI. Furthermore, their involvement allows IMI to link in with other international initiatives tackling shared challenges like diabetes and autism. Their contributions are testament to the attractiveness of IMI's public-private partnership model. Our experience shows that by bringing together the expertise, energy and creativity of groups from different sectors in our projects, it is possible to make progress in even the most challenging areas."

Diabetes and low blood sugar: Many diabetes patients experience hypoglycaemia, when their blood sugar levels become too low. Symptoms include behavioural changes, memory loss and confusion, which can result in accidents and falls and, in the worst cases, in hospitalisation or death. This topic aims to add to our understanding of hypoglycaemia, with the ultimate goal of making it easier for people with diabetes to manage their blood sugar levels.

Prostate cancer and big data: Prostate cancer is the second most common cancer in men, and accounts for 9% of all cancer deaths among men in the EU. The goal of this topic is to identify and use existing real-life patient data to improve outcomes for prostate cancer patients. This topic falls under the IMI Big Data for Better Outcomes (BD4BO) programme.

Pain: Patients with a wide range of conditions may experience pain in the short or long term, and all too often, painkillers prove ineffective. This topic is split into three complementary subtopics. These address the need for patient reported outcomes; the need for better biological markers to facilitate the research and development of treatments; and the challenge of understanding chronic pelvic pain.

Paediatric clinical trials network: Less than half of all authorised medicines commonly used in children have been properly tested in this group. Running clinical trials involving children is hard. There are many operational challenges, such as finding enough patients, and there is no organised, EU-wide clinical trial infrastructure. This topic aims to change that by creating a large, collaborative paediatric network to facilitate the development of drugs for the benefit of children, parents and society.

Biomanufacturing: Animal cell technology is now widely used in drug development, and key to the quality of the final product is the cell culture process. The objective of this topic is to develop high-throughput tools and methods to monitor and manage the cell culture processes during both drug development and manufacture.

Genes and disease: So-called transport proteins are the gate-keepers of our cells, effectively controlling the flow of nutrients and other molecules across the cell membrane. This topic focuses on the solute carriers, which are the largest class of transport proteins, counting over 400 members. The genes that encode solute carrier proteins have been implicated in a number of diseases, including diabetes and cancer, yet many remain to be studied in detail. This topic aims to deliver new tools and methods that will make it easier for scientists to study the solute carrier gene family and develop drugs that target them.

Patient perspectives in research: The goal of this topic is to provide a framework and guidance for all stakeholders on the best ways to meaningfully engage patients at different stages of the medicines lifecycle.

Autism: Autism spectrum disorders (ASD) affect around 1% of the population and are characterised by difficulties in social interactions and communication as well as repetitive behaviours. Efforts to develop effective treatments have so far been unsuccessful, partly because of differences between different groups of patients. This topic will consolidate European clinical research in this area by creating a Europe-wide infrastructure to accelerate and tailor the recruitment of patients for clinical trials, and by validating biomarkers.

Deadline for short proposals: 28 March 2017

For further information, please visit the IMI2 - Call 10 web page:
http://www.imi.europa.eu/content/imi-2-call-10

About the Innovative Medicines Initiative
The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, the next generation of medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, pharmaceutical companies, other companies active in healthcare research, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. This approach has proven highly successful, and IMI projects are delivering exciting results that are helping to advance the development of urgently-needed new treatments in diverse areas.

IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). Through the IMI 2 programme, IMI has a budget of €3.3 billion for the period 2014-2024. Half of this comes from the EU's research and innovation programme, Horizon 2020. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects 'in kind', for example by donating their researchers' time or providing access to research facilities or resources.

Most Popular Now

Artificial Intelligence Solution Improve…

Clinical trials are a critical tool for getting new treatments to people who need them, but research shows that difficulty finding the right volunteer subjects can undermine the effectiveness of...

South West London Pathology Picks CliniS…

One of the first pathology networks in the country, set up to serve more than two million people in south west London, has signed a contract with CliniSys for a...

Call for Tenders: Studies on eHealth, In…

The European Commission is launching a tender for two studies to survey and analyse progress on the digital transformation of the health and care in the EU, in particular with...

AI-based AI-Rad Companion Chest CT Softw…

AI-Rad Companion Chest CT(1), an intelligent software assistant for radiology, was recently awarded the CE mark, which means Siemens Healthineers can start marketing this artificial intelligence (AI)-based software as a...

Spot On for Healthcare Technology Startu…

10 - 12 October 2019, Berlin, Germany. XPOMET Medicinale brings together care providers, patients, and in general stakeholders from all health-related fields and geographic regions. The Festival of Future Medicine and...

Isansys Named as Finalist for OBN's Most…

Isansys Lifecare is proud to announce it has been shortlisted in the Most Transformative Digital Healthcare Company category at the OBN Annual Awards 2019. The award recognises the significant uptake...

7th MEDICA MEDICINE + SPORTS CONFERENCE

18 - 21 November 2019, Düsseldorf, Germany. What lengths do top athletes go to in order to reach peak performances and which findings in the field of professional sports are relevant...

How can We Successfully Converge the Hea…

Opinion Article by Erik Janssen, VP, Innovative Solutions, Neurology, UCB Pharma. The fourth industrial revolution is upon us and fundamentally changing the way we live, work and interact across all industries...

Carestream Health Completes Sale of Heal…

Carestream Healthhas completed the sale of the company's healthcare information solutions business to Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, in 26 of the 38...

Allscripts Listed on Lot One of Health S…

Allscripts has been included on a new list of accredited suppliers of electronic patient records that has been published by NHS England and NHSX. The company is one of just...